Eupraxia Hits 120-Patient Enrollment Target in RESOLVE EoE Trial, December Interim Data Next
EPRX sits 20% above its 52-week low of $5.25.
Summary
Eupraxia enrolled and treated its 120th patient in the placebo-controlled Phase 2b portion of the RESOLVE trial on October 12, hitting its target for EP-104GI in eosinophilic esophagitis. The blinded study randomizes 120 patients 1:1:1 across 120mg, 160mg and vehicle control, and the company says sequestered data reviews confirmed the sample size needs no adjustment. Management also reported no treatment-related serious adverse events across more than 3,000 injections, with many patients now followed for 52 weeks. This follows the 52-week high-dose cohort data disclosed September 30 and the ACG/UEG abstract plans from October 9, keeping the RESOLVE narrative on track. The December 2026 interim analysis — symptoms, histology and safety in the first 60 Phase 2b patients at six months, plus 3-, 9- and 12-month timepoints — is the next hard read on whether EP-104GI works. Enrollment completion de-risks the timeline but is not efficacy data; the stock's move hinges on that December readout.
At the time of this announcement, EPRX was trading at $6.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $434.3M. The 52-week trading range was $5.25 to $9.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.